---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-052948"
form_type: "8-K"
ticker: "SILO"
cik: "0001514183"
company_name: "Silo Pharma, Inc."
filed_at: "2023-06-29T23:59:59+00:00"
generated_at: "2026-06-13T14:50:04.829065+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Silo Pharma extends license agreement with University of Maryland through Sept 2023, with option to Dec 2023

## Summary
- Term of Commercial Evaluation and License Agreement extended to September 30, 2023.
- Company may further extend to December 31, 2023 by paying $2,500 fee and providing notice by August 31, 2023.
- Amendment executed June 28, 2023; fee creditable against future patent expenses if master license signed.

## SEC filing metadata
- accession: 0001213900-23-052948
- form_type: 8-K
- ticker: SILO
- cik: 0001514183
- company_name: Silo Pharma, Inc.
- filed_at: 2023-06-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514183/000121390023052948/0001213900-23-052948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514183/000121390023052948/ea181159-8k_silopharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-052948
- JSON: https://secwatch.observer/filing/0001213900-23-052948.json
- Plain text: https://secwatch.observer/filing/0001213900-23-052948.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.